Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital sees major upside at Hostelworld

(Sharecast News) - Shore Capital has reiterated its 'buy' rating for Hostelworld, hailing the group's social network-led transformation and recent investments to drive long-term growth. The broker gave the stock a fair value estimate of 230p, suggesting significant upside from Friday morning's price of 118p, down 0.4% on the day.

Analysts said Hostelworld has built a "strong foundation of trust" between its customers and suppliers, which is reflected in its performance since Covid, with bookings, revenues and adjusted EBITDA now all back above FY19 levels.

The company's member network - 80% of group bookings from its 2.6m-member network - and content-rich social booking platform are now a valuable part of its investment case, helping retention rates and engagement with the brand, Shore Capital said.

"HSW has built a leading tech-led travel business, which differentiates itself from other OTAs due to its high expertise in hostels, key industry relationships, and now social features. We believe this provides a solid foundation for scaling the business, while retaining an asset-light, cash-generative structure," the broker said.

Shore Capital also highlighted Hostelworld's ambitions to expand its current market coverage - through opportunities in Latin America and Asia - as well other enhancements such as a new ranking system to boost commission rates and a new low-cost customer acquisition channel.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.